The British Journal of Psychiatry (2005) 187: 184-185
© 2005 The Royal College of Psychiatrists
Effect of psychiatric disorders on outcome of cognitive-behavioural therapy for chronic fatigue syndrome
JUDITH PRINS, PhD
Department of Psychology, Radboud University Nijmegen Medical Centre,
Nijmegen, The Netherlands
GIJS BLEIJENBERG, PhD
Expert Centre for Chronic Fatigue, Radboud University Nijmegen Medical
Centre, Nijmegen, The Netherlands
EUFRIDE KLEIN ROUWELER
Department of Medical Psychology, Radboud University Nijmegen Medical
Centre, Nijmegen, The Netherlands
JOS van der MEER, MD, PhD
Department of Internal Medicine, Radboud University Nijmegen Medical
Centre, Nijmegen, The Netherlands
Correspondence:
Dr Judith Prins, University Medical Centre Nijmegen, 118 Medical Psychology,
PO Box 9101, 6500 HB Nijmegen, The Netherlands. E-mail:
j.prins{at}mps.umcn.nl
Declaration of interest None. Funding detailed in
Acknowledgement.

ABSTRACT
Psychiatric disorders have been associated with poor outcome
in individuals
with chronic fatigue syndrome (CFS). This study
examines the impact of
psychiatric disorders on outcome of
cognitive-behavioural therapy (CBT).
Psychiatric diagnoses
were assessed with a structured psychiatric interview in
a
CBT trial of 270 people with CFS. Lifetime and current psychiatric
disorders
were found in 50 and 32% respectively. No significant
differences in fatigue
severity and functional impairment following
treatment were found between
participants with and without
psychiatric diagnoses.

INTRODUCTION
The prevalence of psychiatric disorders in chronic fatigue syndrome
(CFS)
has been obscured by varying CFS criteria, instruments
and research settings
and by symptom overlap (
Wessely et
al, 1998). Studies of psychiatric disorders as predictors of
CFS
prognosis have produced conflicting results
(
Wessely et al,
1998), raising questions about the impact of psychiatric
comorbidity
on the outcome of cognitive-behavioural therapy (CBT), an
effective
therapy for CFS (
Whiting et
al, 2001). When psychiatric diagnoses
were assessed in CBT
trials, their effect on treatment outcome
was not reported
(
Sharpe et al, 1996),
significant differences
in improvement were not found
(
Deale et al, 1997)
and poor
outcome was associated with psychiatric history
(
Bonner et al, 1994).
In our CBT trial, psychiatric comorbidity might
have caused moderate
clinically significant improvement and
a high rate of withdrawal from the
trial (
Prins et al,
2001).
In this study, psychiatric diagnoses in CFS patients will
be
examined in relation to treatment outcome.

METHOD
Sample and procedure
Psychiatric disorders were studied in 270 individuals with CFS
in a
randomised controlled CBT trial (full details:
Prins et al, 2001).
Anxiety disorders, mood disorders, somatoform
disorders and post-traumatic
stress disorder were assessed
at baseline using the Structured Clinical
Interview for DSM-III-R
(SCID-III-R;
Spitzer et al, 1990).
The outcome measures of
fatigue severity, functional impairment, depression
and psychological
distress were assessed at baseline, 8 and 14 months. Fatigue
severity was assessed using a sub-scale of the Dutch Checklist
Individual
Strength (CIS;
Beurskens et al,
2000) and functional
impairment using eight sub-scales of the
Sickness Impact Profile
(SIP;
Bergner
et al, 1976). The Symptom Checklist (SCL-90;
Arrindell et al, 1986)
was used for psychological distress.
The Beck Depression Inventory (BDI;
Beck et al, 1988)
measured
depression. All measures had good reliability and validity.
For comparison we used the published data of a Dutch general population
sample with the same age range, in which the same diagnostic categories of
DSM-III-R mood and anxiety disorders were obtained using a similar clinical
interview (the Composite International Diagnostic Interview; CIDI) during the
same period (Bijl et al,
1998).
Statistical analysis
Lifetime prevalence refers to disorders at some time in a participant's
life and current prevalence refers to disorders at the time of the study.
Controlling for overlap between depression and CFS, mood disorders were
calculated both with and without fatigue and/or poor concentration. We used
Z-scores to compare percentages of psychiatric disorders in the trial
participants and in the general population. Percentages of participants with
and without psychiatric disorders in those completing and not completing the
trial were compared using Fisher's exact test. Main and interaction effects of
psychiatric diagnoses on the outcome variables were analysed with a general
linear model for repeated measurements, with trial condition, current
psychiatric diagnosis and their first-order interactions as independent
variables.

RESULTS
Prevalence of psychiatric disorders
The data of 264 participants were analysed (6 were omitted,
owing to
missing data).
Table 1 shows
that lifetime psychiatric
disorders were present in 50% of participants and
that 28%
had two or more diagnoses. Current psychiatric disorders were
reported by 32.2%, 11% of whom had two or more diagnoses. Lifetime
and current
mood disorders were found in 37.1 and 18.9% respectively,
and lifetime and
current anxiety disorders in 19.7 and 13.3%
respectively. Only two
participants (0.9%) had post-traumatic
stress disorder in remission. Other
current somatoform disorders
were identified in 8.3%, and 4.9% had a lifetime
somatisation
disorder.
View this table:
[in this window]
[in a new window]
|
Table 1 Number and percentage of DSM-III-R diagnoses in the trial sample of
individuals with chronic fatigue syndrome compared with published data of a
Dutch general population sample (de Bijl et al, 1998)
|
Participants with lifetime or current psychiatric disorders were not
significantly different from those without in terms of age, duration of
complaints, education, fatigue and functional impairment. Gender differences
were found in lifetime psychiatric diagnoses (female 53.9% v. male
36.2%, P <50.05), but not in current psychiatric disorders (33%
v. 29%).
Compared with the general population, lifetime and current mood disorders
in the trial participants were significantly higher (37.1% v. 19.1%;
Z=7.2, P <0.0001; 18.9% v. 3.9%;
Z=12.5, P <0.0001). No significant differences were found
between lifetime and current anxiety disorders (19.7% v. 19.3%;
Z=0.16, P=0.87; 13.3% v. 9.7%; Z=1.89,
P=0.058). No significant differences were found between participants
with and without lifetime or current psychiatric diagnoses in the groups of
those who completed or did not complete the trial. After controlling for CFS
symptoms, fatigue and poor concentration, we found lifetime and current mood
disorders in 26.5 and 14% of participants respectively, and lifetime and
current psychiatric disorders in 42.8 and 28.4% respectively.
Psychiatric disorders and treatment outcome
In the outcome variables fatigue severity and functional impairment,
neither main effects of current psychiatric diagnosis (F=0.333,
P=0.564; F=0.209, P=0.209) nor interaction effects
of trial condition and current psychiatric diagnosis (F=0.065,
P=0.937; F=0.848, P=0.430) were found. Participants
with a current psychiatric diagnosis had outcomes almost identical to those
without. In the outcome variables depression and psychological distress, main
effects of current psychiatric diagnosis (F=25.4, P
<0.001; F=20.2, P <0.001) were found but no
interaction effects of trial condition and psychiatric diagnosis
(F=0.067; P=0.935; F=0.306, P=0.737). This
indicated that participants with a current psychiatric diagnosis had higher
BDI and SCL-90 scores at baseline, 8 and 14 months, compared with patients
without a current psychiatric diagnosis, but both groups had similar
difference scores from baseline to post-test and follow-up.

DISCUSSION
The prevalence of psychiatric diagnoses in our sample of individuals
with
CFS seems low to moderate compared with DSM-III-R diagnoses
found in other
studies (
Wessely et al,
1998). As in other
studies, post-traumatic stress disorder was
rare. In contrast
to most studies, in which between 10 and 20% fulfil the
criteria,
less than 5% of our participants screened positive for somatisation
disorder. Lower prevalence rates may be the result of the research
setting, in
which patients with a main complaint of fatigue
were referred to an internal
medicine out-patient clinic. The
specialist might have diagnosed CFS instead
of a psychiatric
disorder or psychiatric symptoms might have been interpreted
as a normal reaction to physical illness. Examiners were not
biased to
diagnose somatisation disorder or other psychiatric
disorders in the trial
participants. Somatic complaints rather
than psychiatric symptoms were our
primary interest.
The question arises whether overdiagnosis explains the higher percentages
of mood disorders in people with CFS than in the general population.
Controlling for CFS symptoms, respectively 9 and 5% fewer mood disorders
resulted. Since more CFS patients were female, a gender effect might also
explain the differences.
In contrast to what we expected, equal treatment effects of CBT were found
for participants with and without current psychiatric disorders. Depression
and psychological distress also benefited from CBT specially tailored for CFS.
Treating psychiatric comorbidity may relieve psychological distress, but does
not alter fatigue severity. Another interesting finding concerned the natural
course of CFS, which was not adversely affected by current psychiatric
comorbidity over 14 months. This confirmed results of an earlier study, in
which depression was not a significant factor in the persistence of CFS
(Vercoulen et al,
1998).

ACKNOWLEDGMENTS
This research was supported by a grant from the Health Insurance
Council
(College voor Zorgverzekeringen).

REFERENCES
- Arrindell, W. A. & Ettema, J. H. M. (1986)
SCL-90, Handleiding bij een Multidimensionele
Psychopathologie-Indicator (in Dutch). Lisse: Swets &
Zeitlinger.
- Beck, A. T., Steer, R. A. & Garbin, M. G.
(1988) Psychometric properties of the Beck Depression
Inventory. Twenty-five years of evaluation. Clinical Psychology
Review, 8, 77
-100.[CrossRef]
- Bergner, M., Bobbitt, R. A., Kressel, S., et al
(1976) The sickness impact profile: conceptual formulation
and methodology for the development of a health status measure.
International Journal of Health Services,
6, 393-415.[Medline]
- Beurskens, A. J. H. M., Bültmann, U., Kant, I. J., et
al (2000) Fatigue amongst working people: validity of a
questionnaire measure. Occupational and Environmental
Medicine, 57, 353
-357.[Abstract/Free Full Text]
- Bijl, R. V., Ravelli, A. & van Zessen, G.
(1998) Prevalence of psychiatric disorder in the general
population: results of the Netherlands Mental Health Survey and Incidence
Study (NEMESIS). Social Psychiatry and Psychiatric
Epidemiology, 33, 587
-595.[CrossRef][Medline]
- Bonner, D., Ron, M., Chalder, T., et al
(1994) Chronic fatigue syndrome: a follow-up study.
Journal of Neurology, Neurosurgery and Psychiatry,
57, 617
-621.[Abstract/Free Full Text]
- Deale, A., Chalder, T., Marks, I., et al
(1997) Cognitive behaviour therapy for chronic fatigue
syndrome: a randomized controlled trial. American Journal of
Psychiatry, 154, 408
-414.[Abstract]
- Prins, J. B., Bleijenberg, G., Bazelmans, E., et al
(2001) Cognitive behaviour therapy for chronic fatigue
syndrome: a multicentre randomised controlled trial.
Lancet, 357, 841
-847.[CrossRef][Medline]
- Sharpe, M., Hawton, K., Simkin, S., et al
(1996) Cognitive behaviour therapy for the chronic fatigue
syn-drome: a randomized controlled trial. BMJ,
312, 22-26.[Abstract/Free Full Text]
- Spitzer, R. L., Williams, J. B., Gibbon, M., et al
(1990) Structured Clinical Interview for DSM-III-R
- Patient Edition.Washington, DC: American Psychiatric
Press.
- Vercoulen, J. H. M. M., Swanink, C. M. A., Galama, J. M. D.,
et al (1998) The persistence of fatigue in chronic
fatigue syndrome and multiple sclerosis: the development of a model.
Journal of Psychosomatic Research,
45, 507
-517.[CrossRef][Medline]
- Wessely, S., Hotopf, M. & Sharpe, M. (1998)
Chronic Fatigue and its Syndromes. Oxford: Oxford
University Press.
- Whiting, P., Bagnall, A., Sowden, A. J., et al
(2001) Interventions for the treatment and management of
chronic fatigue syndrome. JAMA,
286, 1360
-1366.[Abstract/Free Full Text]
Received for publication May 6, 2004.
Revision received January 7, 2005.
Accepted for publication January 18, 2005.
This article has been cited by other articles:

|
 |

|
 |
 
B. Van Houdenhove and P. Luyten
Customizing Treatment of Chronic Fatigue Syndrome and Fibromyalgia: The Role of Perpetuating Factors
Psychosomatics,
November 1, 2008;
49(6):
470 - 477.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Van Houdenhove
Psychiatric comorbidity and chronic fatigue syndrome
The British Journal of Psychiatry,
April 1, 2006;
188(4):
395 - 395.
[Full Text]
[PDF]
|
 |
|